var data={"title":"Topical cocaine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Topical cocaine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5937?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=topical-cocaine-drug-information\" class=\"drug drug_general\">see &quot;Topical cocaine: Drug information&quot;</a> and <a href=\"topic.htm?path=topical-cocaine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Topical cocaine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051861\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Analgesic, Topical</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Local Anesthetic, Topical</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051855\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=topical-cocaine-drug-information\" class=\"drug drug_general\">see &quot;Topical cocaine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Pediatric: <b>Topical anesthetic: </b><b>Note:</b> Concentrations of 1% to 4% are used; use lowest effective dose; consider reduced dosages in children and debilitated patients; dose depends on patient tolerance, anesthetic technique, vascularity of tissue, and area to be anesthetized. Solutions &gt;4% are not recommended due to increased risk and severity of systemic toxicities; maximum total dose:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Children: Topical: 1 to 2 mg/kg/dose (Liao 1999; McGee 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adolescents: Topical: 2 to 3 mg/kg <b>or</b> 200 mg, whichever is lower (Liao 1999; McGee 2010)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154089\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, External, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4% (4 mL, 10 mL); 10% (4 mL [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154073\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154125\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051866\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Topical: Use only on mucous membranes of the oral, laryngeal, and nasal cavities; do not use on extensive areas of broken skin; do not apply commercially available products to the eye </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154106\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); do not freeze. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051865\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Topical anesthesia for mucous membranes of the oral, laryngeal, and nasal cavities (FDA approved in children and adults); has also been used for its vasoconstrictive properties in nasal surgery. <b>Note:</b> Approved ages for pediatric patients may vary among products; consult product specific labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154130\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Use of the topical solution may produce systemic reactions from excessive and rapid absorption.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Decreased heart rate (low doses), myocardial infarction (Lenders 2013; Makaryus 2006), tachycardia, vasoconstriction, ventricular arrhythmia (Lenders 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Central nervous system depression (may follow CNS excitation), central nervous system stimulation, excitation, headache, nervousness, restlessness, tonic-clonic seizures</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Corneal changes (epithelium sloughing), corneal ulcer, mydriasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Epistaxis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare, but important or life-threatening: Increased blood pressure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154095\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to cocaine or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154077\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease or risk factors for cardiovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cocaine abuse: Use with caution in patients with a history of cocaine abuse. In patients being treated for cardiovascular complication of cocaine abuse, avoid beta-blockers for treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acutely ill patients: Use with caution in acutely ill; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Debilitated patients: Use with caution in debilitated patients; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Use with caution in children; reduce dose consistent with age and physical status.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgical patients: Consider anesthesia safe in a cocaine-abusing patient when obvious signs of intoxication are not exhibited (eg, tachycardia, hypertension, hyperthermia, ECG changes including QRS and QT<sub>c</sub> interval prolongation &gt;500 msec) (Hill 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: For topical use only. Limit to office and surgical procedures only. Not for ophthalmic use; causes sloughing of the corneal epithelium. Use caution in patients with severely traumatized mucosa and sepsis in the region of the proposed application.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Trained personnel: Clinicians using local anesthetic agents should be well trained in diagnosis and management of emergencies that may arise from the use of these agents. Resuscitative equipment, oxygen, and other resuscitative drugs should be available for immediate use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154119\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154082\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13177&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: Cocaine (Topical) may enhance the tachycardic effect of Cannabinoid-Containing Products. <b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Cocaine (Topical) may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Cocaine (Topical) may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: Cocaine (Topical) may enhance the hypertensive effect of Sympathomimetics.  Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154084\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13862039\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted with this product. Cocaine rapidly crosses the placenta in concentrations equal to those in the mother. Adverse events occur in the fetus (eg, congenital malformations, growth restriction), infant (neonatal abstinence syndrome), and mother (eg, preterm labor, placental abruption) following maternal abuse (Fajemirokun-Odudeyi, 2004).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1051860\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, blood pressure, respiratory rate, temperature</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154076\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ester local anesthetic blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction; interferes with the uptake of norepinephrine by adrenergic nerve terminals producing vasoconstriction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F154094\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">Following topical administration to mucosa:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: ~1 minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: ~5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration (dose dependent): &ge;30 minutes; cocaine metabolites may appear in urine of neonates up to 5 days after birth due to maternal cocaine use shortly before birth</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Well absorbed through mucous membranes (~35% absorbed when applied intranasally with cottonoid pledget) (Liao 1999); enhanced by inflammation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: &sim;2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic; major metabolites are ecgonine methyl ester and benzoyl ecgonine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 75 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily urine (&lt;10% as unchanged drug and metabolites); cocaine metabolites may appear in the urine of neonates for up to 5 days after birth due to maternal cocaine use shortly before birth</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323076\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Cocaine HCl External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4% (4 mL): $223.12</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038586\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Kokain (DK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Chasnoff IJ, Lewis DE, and Squires L, &ldquo;Cocaine Intoxication in Breast-Fed Infants,&rdquo; <i>Pediatrics</i>, 1987, 80(6):836-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-pediatric-drug-information/abstract-text/3684393/pubmed\" target=\"_blank\" id=\"3684393\">3684393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cocaine hydrochloride [prescribing information]. Cody, WY: Cody Laboratories; March 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fajemirokun-Odudeyi O and Lindow SW, &quot;Obstetric Implications of Cocaine Use in Pregnancy: A Literature Review,&quot; <i>Eur J Obstet Gynecol Reprod Biol</i>, 2004, 112(1):2-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-pediatric-drug-information/abstract-text/14687731/pubmed\" target=\"_blank\" id=\"14687731\">14687731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenglass EJ, &ldquo;The Adverse Effects of Cocaine on the Developing Human,&rdquo; Yaffe SJ and Arana JV, eds, <i>Pediatric Pharmacology: Therapeutic Principles in Practice</i>, 2nd ed, Philadelphia, PA: WB Saunders Co, 1992, 598-604.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hill GE, Ogunnaike BO, Johnson ER. General anaesthesia for the cocaine abusing patient. Is it safe? <i>Br J Anaesth</i>. 2006;97(5):654-657.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-pediatric-drug-information/abstract-text/16914461/pubmed\" target=\"_blank\" id=\"16914461\">16914461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lenders GD, Jorens PG, De Meyer T, Vandendriessche T, Verbrugghe W, Vrints CJ. Coronary spasm after the topical use of cocaine in nasal surgery. <i>Am J Case Rep</i>. 2013;14:76-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-pediatric-drug-information/abstract-text/23569569/pubmed\" target=\"_blank\" id=\"23569569\">23569569</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liao BS, Hilsinger RL Jr, Rasgon BM, et al, &quot;A Preliminary Study of Cocaine Absorption From the Nasal Mucosa,&quot; <i>Laryngoscope</i>, 1999, 109(1):98-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-pediatric-drug-information/abstract-text/9917048/pubmed\" target=\"_blank\" id=\"9917048\">9917048</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makaryus JN, Makaryus AN, Johnson M. Acute myocardial infarction following the use of intranasal anesthetic cocaine. <i>South Med J</i>. 2006, 99(7):759-761.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-pediatric-drug-information/abstract-text/16866061/pubmed\" target=\"_blank\" id=\"16866061\">16866061</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McGee DL, &ldquo;Local and Topical Anesthesia,&rdquo; Roberts JR and Hedges JR, eds, <i>Clinical Procedures in Emergency Medicine</i>, Philadelphia, PA: WB Saunders Co, 2010, 481-498.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rezvani M and Hartfield D, &quot;Cocaine Toxicity After Laryngoscopy in an Infant,&quot; <i>Can J Clin Pharmacol</i>, 2006, 13(2):e232-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/topical-cocaine-pediatric-drug-information/abstract-text/16820655/pubmed\" target=\"_blank\" id=\"16820655\">16820655</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13177 Version 101.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1051861\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1051855\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F154089\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F154073\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F154125\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1051866\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F154106\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1051865\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F154130\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F154095\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F154077\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F154119\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F154082\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F154084\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13862039\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1051860\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F154076\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F154094\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323076\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038586\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13177|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=topical-cocaine-drug-information\" class=\"drug drug_general\">Topical cocaine: Drug information</a></li><li><a href=\"topic.htm?path=topical-cocaine-patient-drug-information\" class=\"drug drug_patient\">Topical cocaine: Patient drug information</a></li></ul></div></div>","javascript":null}